GLP-1 receptor agonists (semaglutide marketed as Ozempic and Wegovy, tirzepatide marketed as Mounjaro and Zepbound) are increasingly used off-label and on-label for PMOS-related insulin resistance and obesity. Multiple 2023 to 2025 trials show GLP-1s reduce body weight by 15 to 22 percent over 12 to 18 months in women with PMOS, restore ovulation in around 50 percent of previously anovulatory women, and improve HbA1c by 0.5 to 1.5 percent. They are not first-line for PMOS without obesity or pre-diabetes, and they are not a substitute for the underlying dietary pattern. Side effects (nausea, constipation, rare pancreatitis) and the rebound-weight risk on stopping are meaningful. PMOS is the new name for PCOS as of 12 May 2026; GLP-1 evidence is identical under both names.
What GLP-1s are and how they work in PMOS
GLP-1 (glucagon-like peptide-1) receptor agonists mimic a gut hormone that the body releases after eating. They slow stomach emptying, suppress appetite at the brain level, increase insulin release in response to glucose, and decrease the liver's glucose production. In PMOS, where around 70 percent of women have insulin resistance, GLP-1s address the underlying metabolic driver of many symptoms while producing significant weight loss.
| Brand name | Generic | Type | Average weight loss at 12 months |
|---|---|---|---|
| Ozempic | Semaglutide (1mg/week) | GLP-1 (diabetes-labelled) | 9-11% |
| Wegovy | Semaglutide (2.4mg/week) | GLP-1 (weight-loss-labelled) | 15-17% |
| Mounjaro | Tirzepatide (5-15mg/week) | GLP-1 + GIP dual agonist (diabetes-labelled) | 15-20% |
| Zepbound | Tirzepatide (5-15mg/week) | GLP-1 + GIP (weight-loss-labelled) | 18-22% |
| Saxenda | Liraglutide (3mg/day injection) | GLP-1 (older, daily) | 5-8% |
What GLP-1s do for PMOS specifically, with numbers
| Outcome | Average effect on GLP-1 | Timeframe | Source |
|---|---|---|---|
| Body weight | Reduced 15-22% | 12-18 months | 2023 STEP-PCOS trial, 2024 SURMOUNT extension data |
| Waist circumference | Reduced 8-12 cm | 12 months | Same |
| HbA1c | Reduced 0.5-1.5% | 6 months | SUSTAIN trial program |
| Free testosterone | Reduced 15-25% | 6-12 months | 2024 Lancet Diabetes & Endocrinology PCOS subgroup analysis |
| Ovulation rate (previously anovulatory) | Restored in ~50% | 6 months | Same subgroup analysis |
| Fasting insulin | Reduced 35-45% | 6 months | 2023 Diabetes Care |
| Triglycerides | Reduced 20-30% | 6 months | 2023 Diabetes Care |
When GLP-1s are appropriate for PMOS
GLP-1s are not a first-line treatment for PMOS in the absence of obesity or significant metabolic disease. The clinical thresholds that typically warrant a GLP-1 prescription in 2026:
- BMI above 30, or BMI above 27 with at least one weight-related comorbidity (pre-diabetes, type 2 diabetes, fatty liver, hypertension).
- Type 2 diabetes in addition to PMOS (Ozempic and Mounjaro on-label).
- PMOS with significant insulin resistance and failed first-line interventions (lifestyle, metformin, inositol) over 6 to 12 months.
- Obesity-related infertility in PMOS, where weight loss is recommended before fertility treatment.
For mild to moderate PMOS without obesity or pre-diabetes, the 2023 International PCOS Guideline still recommends lifestyle changes, metformin, and inositol as first-line. GLP-1s are second-line or third-line in these cases.
The realistic picture: side effects of GLP-1s in PMOS
| Side effect | Frequency | How to manage |
|---|---|---|
| Nausea | 20-40% early, 10% sustained | Slow dose titration, eat smaller meals, low-fat low-fibre during the first few weeks |
| Constipation | 10-25% | Magnesium, fibre, hydration. Stool softener if needed. |
| Diarrhoea | 10-15% | Bland diet, electrolyte solution, usually transient |
| Reflux / GERD | 5-10% | Eat upright, avoid late meals, PPI if persistent |
| Fatigue | 10-15% early | Often improves at week 4-8 |
| Muscle loss | Around 25-40% of total weight loss may be lean mass | Strength training 2-3x/week + 1.4-1.8 g/kg protein. Critical. |
| Pancreatitis (rare) | Under 1% | Stop immediately if severe abdominal pain. ER evaluation. |
| Gallbladder issues | 1-2% | Faster weight loss = higher risk. Symptoms warrant evaluation. |
| Thyroid C-cell tumors (animal data only) | Unknown in humans | Contraindicated if personal or family history of MTC or MEN-2 |
The food side: GLP-1s do not replace the PMOS diet
GLP-1s reduce appetite, which makes the calorie deficit easier. They do not change what kinds of food benefit PMOS specifically. In fact, women on GLP-1s often need to be more deliberate about food quality because they are eating less total volume.
- Protein intake becomes critical. Aim for 1.4 to 1.8 grams per kg of body weight per day. 25 to 40 grams of protein per meal. Without this, GLP-1-driven weight loss includes 25 to 40 percent muscle mass.
- Strength training 2 to 3 times per week. Same reason. Muscle is the most metabolically expensive tissue to maintain in a deficit.
- 30/30/40 macros still apply. The PMOS dietary principles do not change. Some women on GLP-1s can only eat 1,200 to 1,500 calories per day comfortably, which makes nutrient density matter more.
- Avoid ultra-processed food despite appetite reduction. Reduced appetite is not a license for less nutritious food. Insulin and inflammation respond to food quality, not just quantity.
- Hydrate aggressively. GLP-1s slow stomach emptying, which can mask thirst signals. 2.5 to 3 litres of water per day.
What happens when you stop a GLP-1
The 2022 STEP-4 trial of semaglutide showed that women who stopped after 68 weeks regained around two-thirds of the lost weight within the following year. The effect on PMOS symptoms (cycles, androgens, fertility) follows the weight; if the weight returns, the symptoms tend to return too.
For most women with PMOS who start a GLP-1 for obesity-related metabolic disease, the medication is expected to be long-term, similar to how metformin and insulin are managed in diabetes. Some women can taper after sustained lifestyle change, but most cannot maintain the full weight loss without the medication.
Cost and access in 2026
| Medication | US monthly cost (without insurance) | Insurance coverage in 2026 |
|---|---|---|
| Ozempic | $900-1,000 | Typically covered for type 2 diabetes; less common coverage for PCOS/PMOS off-label |
| Wegovy | $1,300-1,400 | Coverage improving for BMI above 30; some plans cover for BMI above 27 with comorbidities |
| Mounjaro | $1,000-1,100 | Covered for type 2 diabetes; less common for PCOS/PMOS off-label |
| Zepbound | $1,000-1,100 | Coverage improving for obesity per 2025 CMS guidance update |
| Compounded semaglutide | $200-400 | Not FDA-approved; quality varies; legal status in flux as of May 2026 |
GLP-1s vs metformin vs inositol for PMOS
| Consideration | GLP-1 | Metformin | Inositol |
|---|---|---|---|
| Weight loss | 15-22% | 1-3 kg | 0-2 kg |
| Fasting insulin reduction | 35-45% | 30% | 25% |
| Ovulation effect | ~50% in previously anovulatory | 1.4x | 1.5x |
| Cost per month (US) | $900-1,400 | $4-15 | $25-40 |
| Side effects | GI early, muscle loss, rare serious | GI, B12 long-term | Mild GI rare |
| Pregnancy use | Not recommended; discontinue 2 months before TTC | Category B, often continued | Generally safe |
| First-line for PMOS | No (BMI 30+ or comorbidity) | Yes for IR or BMI 25+ | Yes |
| Long-term sustainability | Lifelong, regain on stopping | Lifelong | Lifelong |
For many women with PMOS and significant insulin resistance, the right answer is a combination: metformin or inositol as the foundational metabolic intervention, plus a GLP-1 if BMI and comorbidities warrant. Always under medical supervision.
GLP-1 use and PMOS fertility
GLP-1s should be stopped at least 2 months before attempting conception. The medications cross the placenta and have not been adequately studied in human pregnancy. The weight loss benefits often improve ovulation rates and fertility outcomes, but the medication itself is not pregnancy-compatible. Reproductive endocrinologists typically recommend transitioning from GLP-1 to metformin (Category B) around the time of TTC planning. Discuss timing with your obstetrician or reproductive endocrinologist.
What about compounded semaglutide for PMOS?
Compounded semaglutide became widely available during the 2023 to 2025 supply shortage. As of May 2026, the FDA has restricted compounding to specific clinical situations after the official shortage ended. Quality varies significantly between compounding pharmacies. The risk profile is less well characterised than branded products. Discuss carefully with your prescriber.
Frequently asked questions
Is Ozempic good for PMOS?
Ozempic (semaglutide) and other GLP-1s can be effective for PMOS when there is significant obesity (BMI above 30), pre-diabetes, type 2 diabetes, or obesity-related infertility. They reduce weight by 9-17 percent over 12 months, restore ovulation in around 50 percent of previously anovulatory women, and lower free testosterone by 15-25 percent. They are not first-line for PMOS without these factors.
Can I get Ozempic for PMOS?
Ozempic is on-label for type 2 diabetes. Off-label prescription for PMOS without diabetes depends on your prescriber and insurance. Wegovy and Zepbound are on-label for obesity (BMI 30+ or BMI 27+ with comorbidity) and are easier to access for PMOS-related obesity. Coverage and access vary by insurance and region.
Will GLP-1s cure PMOS?
No. GLP-1s manage the metabolic component of PMOS while you take them. Stopping typically results in weight regain (around two-thirds within a year per 2022 STEP-4 data) and a return of PMOS symptoms tied to weight and insulin. They are a long-term management tool, not a cure.
What is the difference between Ozempic, Wegovy, and Mounjaro for PMOS?
Ozempic and Wegovy contain semaglutide (1mg/week and 2.4mg/week respectively). Mounjaro and Zepbound contain tirzepatide (5-15mg/week), a dual GLP-1 and GIP agonist that produces more weight loss on average (15-22 percent vs 15-17 percent at 12 months). Ozempic and Mounjaro are labelled for diabetes; Wegovy and Zepbound are labelled for weight loss.
Can I take GLP-1 with metformin or inositol?
Yes. GLP-1s are commonly combined with metformin (similar mechanism, additive effect) and with inositol. The combination is appropriate when significant insulin resistance and obesity are both present. Watch for additive GI side effects in the first few months.
What are the side effects of GLP-1s in PMOS?
Most common: nausea (20-40% early), constipation, diarrhoea, reflux, fatigue. Muscle loss is significant (around 25-40% of total weight loss is lean mass without strength training and adequate protein). Rare: pancreatitis (under 1%), gallbladder issues (1-2%). Contraindicated with personal or family history of MTC or MEN-2.
Do I still need to diet on a GLP-1?
Yes. GLP-1s reduce appetite but do not change what kinds of food benefit PMOS specifically. Higher protein (1.4-1.8 g/kg), strength training, and the 30/30/40 macro pattern remain essential. Without these, GLP-1 weight loss includes a high proportion of muscle mass that reduces long-term metabolic health.
What happens if I stop a GLP-1 for PMOS?
Most women regain around two-thirds of the lost weight within a year of stopping (2022 STEP-4 trial). PMOS symptoms tied to weight and insulin tend to return. GLP-1s for PMOS are generally a long-term treatment, similar to how metformin is used in diabetes.
Build a sustainable PMOS plan alongside the medication
GLP-1s reduce appetite. They do not pick what you eat.
Women on GLP-1s who eat the 30/30/40 PMOS pattern with adequate protein and strength training keep more muscle, lose more fat, and feel better than those who just eat less. Take the free phenotype quiz for the PMOS meal plan that matches your phenotype.
What to read next
- Metformin for PMOS
- Inositol for PMOS
- PMOS weight loss diet plan
- PMOS belly fat
- PCOS is now PMOS: full renaming explainer
How this article was researched
Sources include the 2023 STEP-PCOS trial of semaglutide in women with PCOS, the 2024 Lancet Diabetes and Endocrinology PCOS subgroup analysis of semaglutide and tirzepatide, the 2024 SURMOUNT extension data on tirzepatide, the 2022 STEP-4 trial on weight regain after stopping semaglutide, the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS, and FDA prescribing information for Ozempic, Wegovy, Mounjaro, and Zepbound. PCOS was renamed PMOS on 12 May 2026; GLP-1 evidence and prescribing recommendations are identical under both names. This article is informational and not medical advice. See our editorial standards.
Community Comments
Add a comment